SCHEMBL23767728

SCHEMBL23767728

COC(=O)Cc1ccc(-c2nccc(OCc3ccccc3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.47
CLK4 Q9HAZ1 1/20 0.43
ALDH1A1 P00352 4/20 0.42
MAPK1 P28482 2/20 0.42
SMPD1 P17405 2/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
PKM P14618 2/20 0.42
HPGD P15428 2/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
XDH P47989 1/20 0.42
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544486 0.88 ALKBH1 (0.49) ALKBH1CLK4ALDH1A1MAPK1SMPD1
SCHEMBL30080246 0.88 ALKBH1 (0.51) ALKBH1ALDH1A1MAPK1SMPD1USP2
SCHEMBL23767729 0.88 ALKBH1 (0.51) ALKBH1ALDH1A1MAPK1SMPD1USP2
SCHEMBL30080394 0.85 ALKBH1 (0.49) ALKBH1ALDH1A1MAPK1SMPD1USP2
SCHEMBL23767730 0.85 ALKBH1 (0.49) ALKBH1ALDH1A1MAPK1SMPD1USP2
SCHEMBL7464319 0.80 PDE5A (0.50) ALKBH1CLK4ALDH1A1MAPK1USP2
SCHEMBL23753904 0.80 SMN1; SMN2 (0.54) ALKBH1CLK4ALDH1A1RAB9ANPC1
SCHEMBL23767893 0.78 KDM5A (0.41) CLK4ALDH1A1CYP1A2RAB9ANPC1
SCHEMBL1163902 0.75 XDH (0.45) ALKBH1CLK4MAPK1CYP1A2CYP3A4
SCHEMBL392863 0.75 ALOX5 (0.66) ALDH1A1CYP1A2RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-01 US disclosed
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-01 US disclosed
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-01 US disclosed
WO-2021160127-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ALKBH1 4349/4885CLK4 3737/4885ALDH1A1 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.